University of California, Los Angeles
This study analyzes the affects or Adderall extended-release (XR) in Subjects receiving brain stimulation therapy for the treatment of Major Depressive Disorder. Subjects will be assigned by chance to active or placebo group. Active group will be asked to take one 15 mg pill once daily of Adderall XR (amphetamine) and the Placebo group will be asked take an identical appearing tablet/capsule, one tablet by mouth daily. The placebo tablet has no active ingredients and has no affect on the body or mind. With the exception of the study drug, all other study activities between both groups will be identical. Subjects will use the assigned study drug two weeks before therapy and throughout the first 10 therapy treatments. A total of seven(7) visits will be required for screening, drug assignment, and completion of mood assessments. This study will enroll a total of 30 Subjects.
This study aims to recruit 30 subjects between the ages of 18-65 who meet the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria for a current episode of major depressive disorder. Participants will be recruited from the population of patients seeking rTMS from the University of California Los Angeles(UCLA) Transcranial Magnetic Stimulation Clinic. All patients considered for participation in the study will carry a diagnosis of major depression as established by the referring psychiatrist and this will be confirmed based on an interview using the Mini International Neuropsy…
Inclusion Criteria: * All subjects will be between the ages of 18-65 and will meet DSM-V criteria for a current episode of major depressive disorder. * Meet criteria for treatment resistance as defined by lack of response to two prior antidepressant trials at adequate dosage and duration. Participants may use any psychotropic medications other than psychostimulants or benzodiazepines, and may continue these medications during the study. * The outside treating psychiatrist must agree that enrollment in the study is safe and acceptable for the subject. Exclusion Criteria: * Inability to give…
Subjects randomized to Adderall XR will initiate treatment with 15 mg daily (one 15 mg tablet each morning) for 21 days.
Subjects randomized to placebo will take an identical-appearing tablet/capsule and, in order to maintain blinding, will also take one tablet by mouth daily. The placebo substance will be sugar for 21 days.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.